Daratumumab for newly diagnosed light chain amyloidosis
Treatments studied
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been newly diagnosed with light chain amyloidosis that affects your heart, kidney, or liver.
- Your disease stage (based on blood tests) fits the study's groups, which includes most stages except the highest risk group in some cases.
- You are generally able to care for yourself (ECOG score 0–2).
- You do not have severe kidney problems (eGFR less than 30), another type of blood cancer like multiple myeloma, or an active infection.
- If you could become pregnant, you must agree to use effective birth control for a year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (teclistamab and daratumumab) for people with AL amyloidosis who have not had prior treatment. The goal is to see if this combination can safely and effectively reduce the abnormal protein deposits in organs.
This study tests a new combination of medicines (daratumumab, bortezomib, and dexamethasone) as the first treatment for people with a specific type of amyloidosis (AL amyloidosis). It aims to see if this combination works better than standard care.
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
This study tests a new medicine called etentamig against a standard combination therapy (Dara-CyBorD) for people with AL amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see which treatment better controls the disease and has fewer side effects.
This trial tests a new device called FreedomEDGE® that gives daratumumab under the skin instead of by an IV. It might make your monthly treatment faster and more comfortable.
This Phase 2 trial studies whether giving daratumumab as ongoing maintenance therapy after your initial AL amyloidosis treatment can improve survival. It may help by keeping the disease under control longer after you have responded to induction therapy.
Hear when a new Light Chain (AL) Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.